Phase 1 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older
- People who self-identify as Black, Asian, Hispanic/Latino, of Mediterranean or Pacific rim heritage, or who tan easily in the sun
- People who are reasonably active and able to carry out daily activities (based on a standard medical scale called ECOG, scoring 0 to 2)
- People who confirm they are not currently pregnant, breastfeeding, or planning to become pregnant or father a child during the study period
- People who have a confirmed diagnosis of breast cancer (verified by tissue testing, with cancer stage recorded)
- People whose radiation treatment is starting within 180 days of surgery if no chemotherapy was given, or within 60 days of the last chemotherapy dose if chemotherapy was received
- People whose treatment plan includes one of several specific types of whole breast, chest wall, or partial breast radiation using standard dose schedules (confirm with trial site for exact doses)
- People whose radiation treatment is photon-based (a common type of radiation beam)
Who may not be able to join:
- People who have previously had radiation therapy to the area planned for treatment
- People currently diagnosed with inflammatory breast cancer, or who have obvious skin involvement at the time radiation is due to start
- People receiving immunotherapy or certain chemotherapy drugs at the same time as radiation (note: targeted HER2 therapy or hormone therapy given at the same time is allowed)
- People who currently have a rash or skin condition in the area to be treated, or who have a history of any rash or skin condition in that area
- People with active connective tissue diseases such as lupus, scleroderma, or dermatomyositis
- People with a history of organ transplant or bone marrow transplant
- People with a known allergy or sensitivity to any ingredient in the study's topical azelaic acid cream
- People who have used certain skin or oral vitamin A-based medications (retinoids), or certain antibiotics known to affect skin or sun sensitivity (such as tetracyclines, erythromycin, sulfamethoxazole, or trimethoprim), in the 28 days before the study baseline
- People who have used steroid, antibiotic, or rash-related skin creams or medications on the breast being treated within 2 weeks before the study baseline
- People whose treatment plan involves proton therapy or carbon therapy
- People whose treatment plan includes certain types of partial breast radiation (external beam partial breast, brachytherapy, or intraoperative radiation)
- People whose medical, psychological, or social circumstances the trial doctors believe could increase risk or make it difficult to follow the study requirements
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Todd C. Adams, MD, Virginia Commonwealth University
Phone: 804-628-6430
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Determine the feasibility of twice daily use of topical azelaic acid in patients undergoing breast radiation therapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.